CS414591A3 - Cytokinin synthesis inhibition factor, antagonists thereof and its use - Google Patents

Cytokinin synthesis inhibition factor, antagonists thereof and its use

Info

Publication number
CS414591A3
CS414591A3 CS914145A CS414591A CS414591A3 CS 414591 A3 CS414591 A3 CS 414591A3 CS 914145 A CS914145 A CS 914145A CS 414591 A CS414591 A CS 414591A CS 414591 A3 CS414591 A3 CS 414591A3
Authority
CS
Czechoslovakia
Prior art keywords
antagonists
inhibition factor
synthesis inhibition
cytokinin synthesis
cytokine
Prior art date
Application number
CS914145A
Other languages
English (en)
Inventor
Timothy R Mosmann
Keving W Moore
Martha W Bond
Paulo J M Vieira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CS414591A3 publication Critical patent/CS414591A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CS914145A 1989-06-28 1991-12-30 Cytokinin synthesis inhibition factor, antagonists thereof and its use CS414591A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37266789A 1989-06-28 1989-06-28
US45395189A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
CS414591A3 true CS414591A3 (en) 1992-12-16

Family

ID=27005854

Family Applications (1)

Application Number Title Priority Date Filing Date
CS914145A CS414591A3 (en) 1989-06-28 1991-12-30 Cytokinin synthesis inhibition factor, antagonists thereof and its use

Country Status (22)

Country Link
EP (2) EP0567450B1 (cs)
JP (1) JP2813063B2 (cs)
KR (1) KR0183035B1 (cs)
CN (3) CN1318589C (cs)
AT (1) ATE180833T1 (cs)
AU (1) AU635058B2 (cs)
CA (1) CA2062763C (cs)
CS (1) CS414591A3 (cs)
DE (1) DE69033143T2 (cs)
DK (1) DK0567450T3 (cs)
ES (1) ES2132068T3 (cs)
FI (1) FI107926B (cs)
GR (1) GR3030404T3 (cs)
HK (2) HK1040493B (cs)
HU (1) HU216310B (cs)
IL (1) IL94878A (cs)
NO (1) NO301718B1 (cs)
NZ (1) NZ234291A (cs)
PT (1) PT94514B (cs)
SG (1) SG52282A1 (cs)
TW (1) TW218383B (cs)
WO (1) WO1991000349A1 (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
US6106823A (en) 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
IE68836B1 (en) * 1991-01-16 1996-07-10 Schering Corp Use of interleukin-10 in adoptive immunotherapy of cancer
JP3260368B2 (ja) * 1991-01-16 2002-02-25 シェリング・コーポレーション インターロイキン−１０による腫瘍性疾患の処置
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
DE69230403T2 (de) * 1991-08-06 2000-05-11 Schering Corp., Kenilworth Verwendung von interleukin-10 analogen oder antagonisten zur behandlung von endotoxin- oder superantigen induzierter toxizität
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
US6884410B1 (en) 1992-03-04 2005-04-26 Schering Corporation Methods for modulating antigen-specific immune responses
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
WO1994004180A2 (en) * 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
JPH08501549A (ja) * 1992-09-18 1996-02-20 スケアリング コーポレイション Ｈｉｖ感染された患者におけるｔヘルパー細胞の免疫担当能力の回復
FI951511L (fi) * 1992-10-01 1995-03-30 Schering Corp IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
AU6000894A (en) * 1993-02-01 1994-08-29 Michel Goldman Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
HUT73463A (en) * 1993-07-26 1996-08-28 Schering Corp Agonists and antagonists of human interleukin-10
US5650060A (en) * 1994-01-28 1997-07-22 Minnesota Mining And Manufacturing Company Ionically conductive agent, system for cathodic protection of galvanically active metals, and method and apparatus for using same
DK0769054T3 (da) 1994-07-05 2000-11-13 Steeno Res Group As Immunmodulatorer
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
CN101307106B (zh) * 1995-12-13 2013-06-12 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
KR20000005539A (ko) * 1996-04-17 2000-01-25 패트릭 티. 프렌더가스트 Dhea복합요법
EP0925072A2 (en) * 1996-09-06 1999-06-30 Schering Corporation Method for lowering cholesterol levels
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US6465176B1 (en) * 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
KR20020091170A (ko) 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
US8491912B2 (en) 2010-06-16 2013-07-23 Allergan, Inc. Methods of treating ocular and other diseases with Syn-134R polypeptide
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE62650B1 (en) * 1989-08-04 1995-02-22 David & Sons Ltd Dispensing apparatus
ZA9010188B (en) * 1989-12-20 1991-08-28 Schering Corp Bcrf1 proteins as inhibitors of interferon-gamma

Also Published As

Publication number Publication date
NZ234291A (en) 1992-11-25
JPH04502560A (ja) 1992-05-14
CN1198642C (zh) 2005-04-27
FI916126A0 (fi) 1991-12-27
HU216310B (hu) 1999-06-28
ES2132068T3 (es) 1999-08-16
AU6077090A (en) 1991-01-17
CN1318589C (zh) 2007-05-30
WO1991000349A1 (en) 1991-01-10
CN1317343A (zh) 2001-10-17
KR0183035B1 (ko) 1999-04-01
CA2062763C (en) 2010-01-05
NO915115D0 (no) 1991-12-27
CN1051393A (zh) 1991-05-15
FI107926B (fi) 2001-10-31
DE69033143D1 (de) 1999-07-08
HK1040531B (zh) 2008-01-11
TW218383B (cs) 1994-01-01
KR920701437A (ko) 1992-08-11
PT94514B (pt) 1998-02-27
JP2813063B2 (ja) 1998-10-22
HUT61048A (en) 1992-11-30
IL94878A0 (en) 1991-04-15
CN1317569A (zh) 2001-10-17
ATE180833T1 (de) 1999-06-15
DE69033143T2 (de) 1999-10-21
HK1040531A1 (en) 2002-06-14
SG52282A1 (en) 1998-09-28
HU906705D0 (en) 1992-03-30
DK0567450T3 (da) 1999-12-13
EP0405980A1 (en) 1991-01-02
HK1040493A1 (en) 2002-06-14
IL94878A (en) 2003-01-12
NO915115L (no) 1992-02-26
HK1008834A1 (en) 1999-05-21
EP0567450A1 (en) 1993-11-03
AU635058B2 (en) 1993-03-11
NO301718B1 (no) 1997-12-01
CA2062763A1 (en) 1990-12-29
PT94514A (pt) 1991-04-18
HK1040493B (zh) 2005-12-16
EP0567450B1 (en) 1999-06-02
GR3030404T3 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
CS414591A3 (en) Cytokinin synthesis inhibition factor, antagonists thereof and its use
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
ES2156852T3 (es) Citoquina mamifera, il-11.
DK20690D0 (da) Alkoxy-1,2,4-triazolo(1,5-c)pyrimidin-2-sulfonamider, fremgangsmaade til deres fremstilling og mellemprodukter
IL94602A0 (en) Polypeptides and polypeptide analogues
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
RU94044322A (ru) Замещенные в кольце z-амино-1,2,3,4-тетрагидронафталины и 3-аминохроманы
NO922456L (no) Bcrf1-proteiner som inhibitorer av interferon-gamma
EP0361284A3 (en) T cell growth factor
ATE111357T1 (de) Synergetische immunostimulierende zusammensetzung und ihre verwendung.
IT8721560A0 (it) Procedimento per la purificazione di interferone.
IT8504867A0 (it) Dispositivo di fissaggio per piastre frontali regolabili di parti di mobile estraibili.
ES8609305A1 (es) Piridiletil-dihidropiridinas
CA2080355A1 (en) Isolated Viral Protein Cytokine Antagonists
MY106292A (en) (alpha)-adrenergic receptor antagonists.
IT8945801A0 (it) Procedimento per la fabbricazione di pannelli sagomati per mobili
IT9045727A0 (it) Procedimento per la fabbricazione di pannelli sagomati per mobili

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic